Aspergillosis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Aspergillosis Treatment Market Analysis

The Aspergillosis Treatment Market size is estimated at USD 4.14 billion in 2024, and is expected to reach USD 5.17 billion by 2029, growing at a CAGR of 4.56% during the forecast period (2024-2029).

The market is expected to grow due to factors like the increasing burden of aspergillosis and other fungal infections, coupled with the rising demand for novel regimens for the management of the condition. Aspergillosis is a severe condition caused by a common mold type, aspergillus. People who have a weakened immune system are at the maximum risk of developing aspergillosis, and the common health issues that arise from the condition are lung infections, allergic reactions, and infections in other areas.

Thus, the severity of the condition has put extensive pressure on pharmaceutical companies to develop novel regimens for managing its symptoms. Some of the commonly used drugs for the treatment of aspergillosis include voriconazole, micafungin, and amphotericin B.

The increasing prevalence of aspergillosis, coupled with the presence of other long-term conditions like asthma, tuberculosis, and cystic fibrosis, have contributed to the high disease burden. For instance, according to data published by the National Organization for Rare Disorders Inc. (NORD) in March 2023, the burden of aspergillosis recorded an increase, and chronic and allergic forms of the condition affected most of the population, making it a major disease type. The data suggested that chronic pulmonary aspergillosis may affect over 3 million people globally, and allergic aspergillosis may affect about 1 to 4 million people globally. Thus, the increasing burden of aspergillosis is alarming and is projected to support industry expansion over the forecast period.

To manage the burden posed by aspergillosis, pharmaceutical companies emphasized more on developing advanced therapies for aspergillosis. Moreover, resistance issues with existing therapies, including corticosteroids and antifungal agents, have further propelled the need for novel solutions for the condition. Thus, pharmaceutical companies are undertaking extensive R&D efforts to develop agents with better efficacy and fewer adverse effects. For instance, in September 2023, Alkem Laboratories and Biosergen collaborated to launch Phase 2 and Phase 3 trials of BSG005 candidates for the treatment of severe fungal diseases in India. The trial enrolled all the people with candidiasis, mucormycosis, and aspergillosis who were resistant or tolerant to amphotericin B.

In addition, in February 2023, Pulmatrix Inc., a leading developer of novel inhaled therapies, took a significant step by dosing the first patient with PUR1900 in a phase 2b trial. This trial aimed to evaluate PUR1900’s potential in the management of allergic bronchopulmonary aspergillosis in people living with chronic pulmonary disorders. This step highlighted market players’ efforts toward developing novel regimens for aspergillosis, thereby fostering market opportunities.

Furthermore, various organic and inorganic initiatives undertaken by market players and rising demand for innovative solutions have further supported industry expansion. For instance, in December 2022, Asahi Kasei Pharma obtained a license to manufacture and commercialize cresemba intravenous infusion 200 mg and cresemba capsule 100 mg in Japan for the management of various fungal infections like cryptococcosis, aspergillosis, and mucormycosis. This helped the company to manage the burden of fungal infections in the country.

Therefore, the above-mentioned factors, including the growing burden of aspergillosis and the increasing efforts from pharmaceutical companies to develop promising therapies for it, are anticipated to propel market growth over the forecast period.

However, limited treatment options, long-term treatment, and resistance issues from current treatment approaches are likely to hamper market growth during the study period.

Aspergillosis Treatment Market Trends

Antifungal Agents Segment is Expected to Hold a Major Market Share in the Global Aspergillosis Treatment Market

Aspergillosis Treatment Industry Segmentation

As per the scope of the report, aspergillosis treatment mainly consists of various antifungal agents and corticosteroids. Aspergillosis is a group of disorders caused by fungi known as Aspergillus. The conditions mainly affect people with compromised immune conditions.

The aspergillosis treatment market is segmented by type, drug class, route of administration, distribution channel, and geography. Based on type, the market is segmented as allergic aspergillosis, chronic aspergillosis, invasive aspergillosis, and aspergillomas. On the basis of drug class, the market is segmented into antifungal agents and other drug classes. Based on the route of administration, the market is segmented as oral drugs, ointments, powders, and other routes of administration. Based on distribution channel, the market is segmented as hospital pharmacy, retail pharmacy, and other distribution channels. The report also covers the market sizes and forecasts for the aspergillosis market in major countries across different regions. For each segment, the market size is provided in terms of value (USD).